Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, 03 1995, 760-762, Vol 39, No. 3
RJ Rice, V Bhullar, SH Mitchell, J Bullard and JS Knapp
The in vitro susceptibilities of 45 recent clinical isolates of Chlamydia
trachomatis obtained from women with asymptomatic genital tract infection,
mucopurulent cervicitis, or pelvic inflammatory disease to doxycycline,
azithromycin, ofloxacin, and clindamycin were determined. In addition,
susceptibilities of 12 isolates to amoxicillin and
trimethoprim-sulfamethoxazole were also determined. Isolates also were
serotyped with a panel of monoclonal antibodies specific for chlamydial
major outer membrane protein; 24 of 45 (53%) belonged to serovars Ia and E.
For all isolates, the MIC range of doxycycline was 0.008 to 0.06
micrograms/ml, for trimethoprim-sulfamethoxazole it was 0.03 to 0.25
micrograms/ml, for azithromycin it was 0.125 to 2.0 micrograms/ml, for
ofloxacin it was 0.5 to 1.0 micrograms/ml, for clindamycin it was 0.25 to
2.0 micrograms/ml, and for amoxicillin it was 0.25 to 4.0 microgram/ml. The
ranges of minimum chlamydiacidal concentrations were generally 1 to 4
dilutions above the MICs of most agents, with a rank order similar to those
of the MICs. Comparing the minimum chlamydiacidal concentrations for 90% of
isolates tested, isolates causing asymptomatic infection belonged to a
greater variety of serovars and were relatively more susceptible to
doxycycline and azithromycin than isolates causing mucopurulent cervicitis
or pelvic inflammatory disease; these differences in susceptibility were
not detected among the other study agents. These data indicate that
additional studies are needed to better define the apparent association of
certain chlamydial serovars with the clinical severity of disease and the
in vitro susceptibilities to certain antimicrobial agents.
Copyright © 1995 by the American Society for Microbiology. All rights reserved.
Susceptibilities of Chlamydia trachomatis isolates causing uncomplicated female genital tract infections and pelvic inflammatory disease
Division of Sexually Transmitted Diseases Laboratory Research, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA.
This article has been cited by other articles:
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |